GetTopicDetailResponse(id=dbce1e071e4, topicName=TACE, introduction=TACE, content=null, image=null, comments=2, allHits=2255, url=https://h5.medsci.cn/topic?id=17071, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=1106, tagList=[TagDto(tagId=1106, tagName=TACE)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2224209, encodeId=e6122224209d5, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a> <a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a> <a href='/topic/show?id=da23e693982' target=_blank style='color:#2F92EE;'>#系統(tǒng)治療#</a>, objectTitle=賈曉黎教授：中晚期肝癌的TACE聯(lián)合系統(tǒng)治療, objectType=article, longId=841798, objectId=02e7841e989f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240723/1721699880262_92910.jpg, objectUrl=/article/show_article.do?id=02e7841e989f, replyNumber=0, likeNumber=125, createdTime=2024-09-05, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=02e7841e989f, moduleTitle=賈曉黎教授：中晚期肝癌的TACE聯(lián)合系統(tǒng)治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=02e7841e989f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205439, encodeId=922c220543966, content=<a href='/topic/show?id=370d8126914' target=_blank style='color:#2F92EE;'>#肝癌#</a> <a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a>, objectTitle=權(quán)威解讀！滕皋軍院士團(tuán)隊：中位生存期近23個月，晚期肝癌一線療法再添新證據(jù), objectType=article, longId=826458, objectId=50898264585b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240518/1716041015451_5579292.jpg, objectUrl=/article/show_article.do?id=50898264585b, replyNumber=0, likeNumber=133, createdTime=2024-05-18, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=50898264585b, moduleTitle=權(quán)威解讀！滕皋軍院士團(tuán)隊：中位生存期近23個月，晚期肝癌一線療法再添新證據(jù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=50898264585b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200547, encodeId=f1f0220054e8c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a> <a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a>, objectTitle=European?Radiology:TACE聯(lián)合camrelizumab+阿帕替尼在HCC患者中的實際療效和安全性評估, objectType=article, longId=823441, objectId=57dc82344176, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867576310_4754896.jpeg, objectUrl=/article/show_article.do?id=57dc82344176, replyNumber=0, likeNumber=123, createdTime=2024-04-26, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=57dc82344176, moduleTitle=European?Radiology:TACE聯(lián)合camrelizumab+阿帕替尼在HCC患者中的實際療效和安全性評估, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=57dc82344176)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1064957, encodeId=b93d106495e08, content=<a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a>研究表明，對于LDH>192 U / L的中期HCC患者，肝切除術(shù)(HR)優(yōu)于TACE。而TACE可能適用于LDH水平≤192 U/L的患者。, objectTitle=TACE, objectType=topic, longId=17071, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=129, createdTime=2021-10-29, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=915934, encodeId=7a2991593422, content=<a href='/topic/show?id=dbce1e071e4' target=_blank style='color:#2F92EE;'>#TACE#</a>單獨應(yīng)用于<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝細(xì)胞癌#</a>是不是合適？如果是現(xiàn)在，更傾向結(jié)合免疫治療，可能會有更好的作用吧, objectTitle=Eur Radiol：合并累及血管的肝細(xì)胞肝癌患者經(jīng)姑息TACE治療效果如何？, objectType=article, longId=205664, objectId=7fb72056643d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021112/1610423762023_1605392.jpg, objectUrl=/article/show_article.do?id=7fb72056643d, replyNumber=0, likeNumber=308, createdTime=2021-01-12, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb72056643d, moduleTitle=Eur Radiol：合并累及血管的肝細(xì)胞肝癌患者經(jīng)姑息TACE治療效果如何？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7fb72056643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
